It was a pleasure to meet with Prof. Andrea Rubbert-Roth (Kantonsspital St Gallen, St Gallen, Switzerland) to discuss the comparative efficacy of upadacitinib and abatacept in patients with rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
The abstract ‘Clinical responses to upadacitinib or abatacept in patients with rheumatoid arthritis by type of prior biologic disease-modifying antirheumatic drug: Data from the phase 3 SELECT-CHOICE study.‘ was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
- What did the SELECT-CHOICE study show us in terms of the comparative efficacy of upadacitinib and abatacept in patients with rheumatoid arthritis with inadequate response or intolerance to biologic disease-modifying antirheumatic drugs? (0:22)
- What were the objectives of the analysis you are presenting? (1:09)
- What were the findings of this analysis? (1:55)
- What were the limitations of the analysis? (3:42)
- How will these findings impact the future use of JAK inhibitors in routine clinical practice? (4:30)
Disclosures: Andrea Rubbert-Roth discloses receiving honoraria for lectures and consultations from Abbvie, UCB, Gilead, Lilly, Pfizer, MSD, Sanofi, Roche and BMS.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
Share this Video
Related Videos In Rheumatoid Arthritis
Roy Fleischmann, ACR 2021: Efficacy and Safety of Olokizumab plus Methotrexate in a Placebo and Active Controlled Study
Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) discusses the results from the phase 3, head-to-head, randomized, placebo-controlled clinical trial investigating olokizumab in patients with active rheumatoid arthritis inadequately controlled with methotrexate, with a comparator arm of adalimumab. This information is brought to you by Touch Medical Media and is not […]
Roy Fleischmann, ACR 2021: Safety and Efficacy of Tofacitinib vs TNF Inhibitors in ORAL Surveillance
It was a pleasure to speak with Dr Roy Fleischmann (University of Texas Southwestern Medical Center, Dallas, TX, USA) about ORAL Surveillance (NCT02092467). Mandated by the FDA, due to observed increases in lipids and malignancies in patients with RA treated with tofacitinib, this study was designed to investigate the relative risk of tofacitinib compared to […]
Gilles Boire, ACR 2021: A Mindfulness-Based Program to Improve PROs in patients with Rheumatoid Arthritis
It was a pleasure to discuss with Prof. Gilles Boire (Université de Sherbrooke, Québec, Canada) the recent pilot study in which a Mindfulness-Based Stress Reduction (MBSR) program was offered to patients with controlled rheumatoid arthritis but elevated negative PROs. This information is brought to you by Touch Medical Media and is not sponsored by, nor […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!